Your browser doesn't support javascript.
loading
Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT.
Tessoulin, B; Delaunay, J; Chevallier, P; Loirat, M; Ayari, S; Peterlin, P; Le Gouill, S; Gastinne, T; Moreau, P; Mohty, M; Guillaume, T.
Afiliación
  • Tessoulin B; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] INSERM CRCNA, UMR 892, Nantes, France.
  • Delaunay J; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] INSERM CRCNA, UMR 892, Nantes, France [3] Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France.
  • Chevallier P; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] INSERM CRCNA, UMR 892, Nantes, France [3] Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France.
  • Loirat M; Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France.
  • Ayari S; Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France.
  • Peterlin P; Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France.
  • Le Gouill S; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] INSERM CRCNA, UMR 892, Nantes, France [3] Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France [4] Université de Nantes, Nantes, France.
  • Gastinne T; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France.
  • Moreau P; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] INSERM CRCNA, UMR 892, Nantes, France [3] Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France [4] Université de Nantes, Nantes, France.
  • Mohty M; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] INSERM CRCNA, UMR 892, Nantes, France [3] Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France [4] Université de Nantes, Nantes, France.
  • Guillaume T; 1] Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Nantes, France [2] INSERM CRCNA, UMR 892, Nantes, France [3] Centre d'Investigation Clinique en Cancérologie (CI2C), Nantes, France.
Bone Marrow Transplant ; 49(4): 567-71, 2014 Apr.
Article en En | MEDLINE | ID: mdl-24488048
Patients with hematopoietic malignancies relapsing after allogeneic hematopoietic SCT (allo-HSCT) have a poor prognosis. We retrospectively analyzed the patients who received azacitidine in our center in the course of treatment of their post-transplant relapse. We identified 31 patients. Relapse occurred at a median of 3.7 (1.7-37.6) months following allo-HSCT. Patients received a median number of three cycles (1-12) of azacitidine (7 days, 75 mg/m(2) daily). Thirty-nine percent of patients had either a monosomal karyotype or a complex karyotype. Eleven patients (35%) received at least one DLI. Eleven patients responded to azacitidine, with four patients achieving a CR (13%). Median time to best response was 92 (35-247) days, with a median duration of 209 (64-751) days. One-year estimated survival rate was 14%. In conclusion, azacitidine may reinduce durable remissions in very few patients with AML or myelodysplastic syndrome. The toxicity related to azacitidine was high, although it may be difficult to distinguish between treatment-related side effects, namely due to cytopenia and toxicity due to the relapse or disease progression itself. Early administration of azacitidine after transplant followed by DLI should be considered as a pre-emptive therapy for potential relapse in patients with minimal residual disease or high-risk myeloid malignancies.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azacitidina / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azacitidina / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido